Extraordinary Shareholder’s Meeting - January 25, 2021

Pr. Bart Staels

Co-founder of GENFIT, Chairman of the Scientific Advisory Board

Bart Staels has a PhD in Pharmacology from the University of Leuven in Belgium, and is Full Professor at the Faculty of Pharmacy, University of Lille, France. He is Director of the Inserm Unit UMR 1011 (ranked excellent by AERES, the French agency evaluating research and higher education institutions, and Inserm), with laboratories located on the Institut Pasteur and Medical Research campuses in Lille.

Throughout his career, his research has focused on the pathophysiological mechanisms and molecular pharmacology of cardiovascular and metabolic diseases. In particular, he has studied the role of nuclear receptors in controlling inflammation, metabolism, lipid and glucose homeostasis as well as the transcription mechanisms involved. Bart Staels is a member of several learned societies such as the European Atherosclerosis Society (EAS), the International Atherosclerosis Society (IAS -distinguished member), the French Atherosclerosis Society (NSFA – past-president), the French Diabetes Society (SFD), the European Association for the Study of Diabetes (EASD), the European and American Associations for the Study of Liver Disease (EASL and AASLD).

He was awarded the Young Investigator prize by the EAS, the bronze medal by the CNRS (National Scientific Research Center), the Lifetime Achievement Award by the British Atherosclerosis Society, the Barré pharmaceutical prize from the Faculty of Pharmacy of Montreal, the JP Binet prize by the French Foundation of Medical Research and the “Distinguished Leader in Insulin Resistance” prize by the International Committee for Insulin Resistance (ICIR).

He is the author of more than 820 scientific publications including 200 review articles and several book chapters.